Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: Clinical and endocrine effects

European Journal of Cancer

Volumn 32, Issue 5, 1996, Pages 789-792

  Geisler, J ^a   Johannessen, D C ^a   Anker, G ^a   Lonning P E ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

Aminoglutethimide; Aromatase inhibitor; Breast cancer; Endocrine treatment; Formestane

Indexed keywords

AMINOGLUTETHIMIDE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTRADIOL; ESTRONE; ESTRONE SULFATE; FLUOROURACIL; FORMESTANE; MITOMYCIN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BREAST CANCER; CLINICAL ARTICLE; FEMALE; HORMONAL THERAPY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; AMINOGLUTETHIMIDE; ANDROSTENEDIONE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED;

EID: 0030007732     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00623-0     Document Type: Article

References (23)

1. Cash RA, Brough AJ, Cohen MNP, Satoh PS. Aminoglutethimide (Ellipten-CIBA) as an inhibitor of adrenal steroidogenesis. Mechanisms of action and therapeutic trial. J Clin Endocr Metab 1967, 27, 1239-1248.
2. Hughes SWM, Burley DM. Aminoglutethimide: a 'side-effect' turned to therapeutic advantage. Postgrad Med J 1970, 46, 409-416.
3. Coombes RC, Goss P, Dowsett M, Gazet JC, Brodie AMH. 4-Hydroxyandrostenedione treatment of postmenopausal patients with advanced breast cancer. Lancet 1984, i, 1237-1239.
4. Goss PE, Powles TJ, Dowsett M, et al. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report. Cancer Res 1986, 46, 4823-4826.
5. Höffken K, Jonat W, Possinger K, et al. Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study. J Clin Oncol 1990, 8, 875-880.
6. Bajetta E, Zilembo N, Buzzoni R, et al. Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer. Br J Cancer 1994, 70, 145-150.
7. Kvinnsland S, Lønning PE, Dahl O. Treatment of breast carcinoma with aminoglutethimide. Acta Rad Oncol 1984, 23, 421-424.
8. Elomaa I, Blomqvist C, Rissanen P. Aminoglutethimide as second line therapy in advanced breast cancer. Breast Cancer Res Treat 1986, 7 (Suppl.), 51-54.
9. Santen RJ, Worgul TJ, Lipton A, et al. Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. Ann Intern Med 1982, 96, 94-101.
10. Vermeulen A, Paridaens R, Heuser JC. Effects of aminoglutethimide on adrenal steroid secretion. Clin Endocrinol 1983, 19, 673-682.
11. Dowsett M, Goss PE, Powles TJ, et al. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res 1987, 47, 1957-1961.
12. Lønning PE, Johannessen DC, Thorsen T. Alterations in the production rate and metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide. Br J Cancer 1989, 60, 107-111.
13. Reed MJ, Lai LC, Owen AM, et al. Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer. Cancer Res 1990, 50, 193-196.
14. Jones AL, MacNeill F, Jacobs S, Lønning PE, Dowsett M, Powles TJ. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. Eur J Cancer 1992, 28A, 1712-1716.
15. MacNeill FA, Jones AL, Jacobs S, et al. The influence of Aminoglutethimide and its analogue Rogletimide on peripheral aromatisation in breast cancer. Br J Cancer 1992, 66, 692-697.
16. Lønning PE, Ekse D. A new sensitive radioimmunoassay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors. J Steroid Biochem 1995, 55, 409-412.
17. Lønning PE, Helle SI, Johannessen DC, et al. Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in postmenopausal breast cancer patients. Clin Endocrinol 1995, 42, 23-30.
18. Hayward JL, Rubens RD, Carbone PP, Heuson JC, Kumaoke S, Segaloff A. Assessment of response to therapy in advanced breast cancer. Br J Cancer 1977, 35, 292-298.
19. Lønning PE, Dowsett M, Jones A, Ekse D, Jacobs S, MacNeill F, Johannessen DC and Powles TJ. Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment. Breast Cancer Res Treat 1992, 23, 57-62.
20. Murray R, Pitt P. Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast Cancer Res Treat 1995, 35, 249-253.
21. Dowsett M, Cunningham DC, Stein RC, Evans S. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res 1989, 49, 1306-1312.
22. Miller WR. Importance of intratumoural aromatase and its suceptibility to inhibitors. In Dowsett M. Aromatase Inhibition. Carnforth, Parthenon Publishing, 1994, 43-51.
23. Johannessen DC, Adlercreutz H, Fotsis T, Lønning PE. Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxyandrostenedione. Br J Cancer 1993, 68, 393-398.